drugset / Trial / NCT06464991
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomid-refractory RRMM who have received 1-2 lines of prior therapy.
Timeline
- Start
- 2024-03-27
- Primary completion
- 2027-08
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Comparator | Daratumumab | Monoclonal antibody | 16 mg/kg | — |
| Comparator | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Equecabtagene Autoleucel | Cell therapy | 1e+06 cells/kg | — |
| Comparator | Pomalidomide | Other / unclassified | 4 mg | — |